High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery.

The application of rapid methods currently used for screening discovery drug candidates for metabolism and pharmacokinetic characteristics is discussed. General considerations are given for screening in this context, including the criteria for good screens, the use of counterscreens, the proper sequencing of screens, ambiguity in the interpretation of results, strategies for false positives and negatives, and the special difficulties encountered in drug metabolism and pharmacokinetic screening. Detailed descriptions of the present status of screening are provided for absorption potential, blood-brain barrier penetration, inhibition and induction of cytochrome P450, pharmacokinetics, biotransformation, and computer modeling. Although none of the systems currently employed for drug metabolism and pharmacokinetic screening can be considered truly high-throughput, several of them are rapid enough to be a practical part of the screening paradigm for modern, fast-moving discovery programs.

[1]  The search for orally active medications through combinatorial chemistry , 1998, Medicinal research reviews.

[2]  D. Egan,et al.  Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides. , 1993, Journal of medicinal chemistry.

[3]  S. Chong,et al.  Prodrugs of BMS-183920: metabolism and permeability considerations. , 1996, Journal of pharmaceutical sciences.

[4]  F. Beaudry,et al.  In vivo pharmacokinetic screening in cassette dosing experiments; the use of on-line Pprospekt liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry technology in drug discovery. , 1998, Rapid communications in mass spectrometry : RCM.

[5]  G. Caldwell,et al.  In vitro permeability of eight beta-blockers through Caco-2 monolayers utilizing liquid chromatography/electrospray ionization mass spectrometry. , 1998, Journal of mass spectrometry : JMS.

[6]  R. Ad,et al.  Application of Human Liver Microsomes in Metabolism-Based Drug-Drug Interactions: In Vitro-in Vivo Correlations and the Abbott Laboratories Experience , 1997 .

[7]  Walter A. Korfmacher,et al.  HPLC-API/MS/MS : a powerful tool for integrating drug metabolism into the drug discovery process , 1997 .

[8]  P. Fernandes,et al.  Technological advances in high-throughput screening. , 1998, Current Opinion in Chemical Biology.

[9]  M H Tarbit,et al.  High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. , 1998, Current opinion in chemical biology.

[10]  F. Guengerich,et al.  Role of cytochrome P450 enzymes in drug-drug interactions. , 1997, Advances in pharmacology.

[11]  G. Grass,et al.  Evaluation of the performance of controlled release dosage forms of ticlopidine using in vitro intestinal permeability and computer simulations. , 1994, Journal of drug targeting.

[12]  D S Wright,et al.  Sample pooling to expedite bioanalysis and pharmacokinetic research. , 1998, Journal of pharmaceutical and biomedical analysis.

[13]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[14]  S. Sisenwine,et al.  Rapid drug metabolite profiling using fast liquid chromatography, automated multiple-stage mass spectrometry and receptor-binding. , 1999, Journal of chromatography. A.

[15]  K. Brouwer,et al.  Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[16]  P. Augustijns,et al.  Use of Caco-2 cells and LC/MS/MS to screen a peptide combinatorial library for permeable structures. , 1999, International journal of pharmaceutics.

[17]  B. W. Penman,et al.  Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. , 1997, Analytical biochemistry.

[18]  C. Hop,et al.  Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. , 1998, Journal of pharmaceutical sciences.

[19]  J G Houston,et al.  The chemical-biological interface: developments in automated and miniaturised screening technology. , 1997, Current opinion in biotechnology.

[20]  Ajay,et al.  Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.

[21]  A. Alex,et al.  Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[22]  T. Olah,et al.  A direct technique for the simultaneous determination of 10 drug candidates in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry interfaced to a Prospekt solid-phase extraction system. , 1997, Journal of pharmaceutical and biomedical analysis.

[23]  D. Miller,et al.  Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. , 1998, Biochemical and biophysical research communications.

[24]  H. Tsuzuki,et al.  Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. , 1999, Journal of medicinal chemistry.

[25]  J. Soloweij,et al.  Lead development: validation and application of high throughput screening for determination of pharmacokinetic parameters for enzyme inhibitors. , 1996, Bioorganic & medicinal chemistry.

[26]  I. Wilson,et al.  Directly coupled HPLC-NMR and its application to drug metabolism. , 1997, Drug metabolism reviews.

[27]  Paavo Honkakoski,et al.  The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene* , 1999, The Journal of Biological Chemistry.

[28]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[29]  Walter A. Korfmacher,et al.  Demonstration of the capabilities of a parallel high performance liquid chromatography tandem mass spectrometry system for use in the analysis of drug discovery plasma samples. , 1999, Rapid communications in mass spectrometry : RCM.

[30]  J. Whitlock,et al.  Induction of cytochrome P4501A1. , 1999, Annual review of pharmacology and toxicology.

[31]  A. Nomeir,et al.  Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes. , 1999, Drug Metabolism And Disposition.

[32]  R. Plumb,et al.  Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. , 1998, Rapid communications in mass spectrometry : RCM.

[33]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[34]  C. Ioannides,et al.  Structural and functional integrity of precision-cut liver slices in xenobiotic metabolism: a comparison of the dynamic organ and multiwell plate culture procedures. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[35]  C. Pidgeon,et al.  IAM chromatography: an in vitro screen for predicting drug membrane permeability. , 1995, Journal of medicinal chemistry.

[36]  K. Carroll,et al.  Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured rat hepatocytes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[37]  S. Ekins,et al.  Xenobiotic metabolism in rat, dog, and human precision-cut liver slices, freshly isolated hepatocytes, and vitrified precision-cut liver slices. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[38]  K. Adkison,et al.  Use of "N-in-One" dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationships. , 1999, Journal of pharmaceutical sciences.

[39]  F. Loor,et al.  Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. , 1996, Anti-cancer drugs.

[40]  M H Tarbit,et al.  Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[41]  K. Brendel,et al.  Liver slices as a model in drug metabolism. , 1997, Advances in pharmacology.

[42]  M K Bayliss,et al.  High-throughput pharmacokinetics: cassette dosing. , 1999, Current opinion in drug discovery & development.

[43]  T. Sueyoshi,et al.  The Nuclear Orphan Receptor CAR-Retinoid X Receptor Heterodimer Activates the Phenobarbital-Responsive Enhancer Module of the CYP2B Gene , 1998, Molecular and Cellular Biology.

[44]  Rees,et al.  Molecular diversity and its analysis. , 1999, Drug discovery today.

[45]  J H Lin,et al.  Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[46]  J. Broach,et al.  New assay technologies for high-throughput screening. , 1998, Current opinion in chemical biology.

[47]  A. Persidis.  High-throughput screening , 1998, Bio/Technology.

[48]  Walter A. Korfmacher,et al.  Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats , 1999 .

[49]  A. Seelig.  A general pattern for substrate recognition by P-glycoprotein. , 1998, European journal of biochemistry.

[50]  B. Kemper,et al.  Sex- and tissue-specific expression of a cytochrome P450 2C2-luciferase transgene , 1996, Molecular and Cellular Endocrinology.

[51]  S. Clarke.  In vitro assessment of human cytochrome P450. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[52]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[53]  M H Tarbit,et al.  Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[54]  Y Zhang,et al.  Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. , 1998, Journal of pharmaceutical sciences.

[55]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[56]  T. Baillie,et al.  Rapid liquid chromatography with tandem mass spectrometry-based screening procedures for studies on the biotransformation of drug candidates. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[57]  H. Kubinyi,et al.  A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.

[58]  Grazyna D. Szklarz,et al.  Molecular modeling of cytochrome P450 3A4 , 1997, J. Comput. Aided Mol. Des..

[59]  T. Baillie,et al.  In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[60]  J. Lin,et al.  Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[61]  Walter A. Korfmacher,et al.  Pharmacokinetic screening for the selection of new drug discovery candidates is greatly enhanced through the use of liquid chromatography-atmospheric pressure ionization tandem mass spectrometry. , 1997, Journal of chromatography. A.

[62]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[63]  T. Thompson.  Experimental models for evaluating enzyme induction potential of new drug candidates in animals and humans and a strategy for their use. , 1997, Advances in pharmacology.

[64]  M. Tarbit,et al.  A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[65]  Walter A. Korfmacher,et al.  Development of an automated mass spectrometry system for the quantitative analysis of liver microsomal incubation samples: a tool for rapid screening of new compounds for metabolic stability. , 1999, Rapid communications in mass spectrometry : RCM.

[66]  M. Davis,et al.  Identification of drug metabolites in biological matrices by intelligent automated liquid chromatography/tandem mass spectrometry. , 1998, Rapid communications in mass spectrometry : RCM.

[67]  P Burkhard,et al.  The discovery of steroids and other novel FKBP inhibitors using a molecular docking program. , 1999, Journal of molecular biology.

[68]  J B Houston,et al.  Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.

[69]  T. Olah,et al.  The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. , 1997, Rapid communications in mass spectrometry : RCM.

[70]  F. Guengerich,et al.  Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.

[71]  O. Fardel,et al.  Use of human hepatocyte cultures for drug metabolism studies. , 1993, Toxicology.

[72]  T. Andersson,et al.  Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. , 1999, The Journal of pharmacology and experimental therapeutics.

[73]  G. Williams,et al.  Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. , 1996, Pharmacology & therapeutics.

[74]  J. Broach,et al.  High-throughput screening for drug discovery. , 1996, Nature.

[75]  B. Kennedy,et al.  Refinement of an in vitro cell model for cytochrome P450 induction. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[76]  A. Li,et al.  Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. , 1997, Chemico-biological interactions.

[77]  D. Lewis,et al.  Molecular modelling of mammalian CYP2B isoforms and their interaction with substrates, inhibitors and redox partners. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[78]  A. Nomeir,et al.  Validation of a rapid microtiter plate assay to conduct cytochrome P450 2D6 enzyme inhibition studies , 1998 .

[79]  Y. Sugiyama,et al.  Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.

[80]  W. Rubas,et al.  A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. , 1997, Critical reviews in therapeutic drug carrier systems.

[81]  Crespi.  Assessing the potential for drug-drug interactions in an accelerated throughput mode. , 1999, Pharmaceutical science & technology today.

[82]  A G Swanson,et al.  High-performance liquid chromatography/NMR spectrometry/mass spectrometry: further advances in hyphenated technology. , 1997, Journal of mass spectrometry : JMS.

[83]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[84]  J. Bolton,et al.  Metabolic screening using on-line ultrafiltration mass spectrometry. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[85]  O Pelkonen,et al.  Inhibition and induction of human cytochrome P450 (CYP) enzymes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.